Overview

Price chart · mood · technical indicators

JNJ

Johnson & Johnsonstock Healthcare

Drug Manufacturers - General

$224.2045.14%Current Market Mood:Neutral

Market Mood

Price Range (1Y)

$146.12$251.71

Current: $224.20

Idea: EMA

1Y Return

+41.0%

Sharpe 3Y

0.75

Market Comparison

vs Healthcare Sector & Drug Manufacturers - General Industry

JNJ

+45.14%

1Y Performance

Healthcare

Sector 1Y

Drug Manufacturers - General

Industry 1Y

Fundamentals

Updated daily after market close

P/E ratio26.33Forward 19.65

EPS (TTM)$8.63-52.9% YoY

Profit margin21.8%HEALTHCARE

Market cap$546.90BMega cap

Wall Street coverage

$252.42median target· current $148.58 (+69.9%)25 analysts

Via 3rd party. Not a recommendation or advice by The Balanced Investor Club. See disclaimer.

Valuation

Forward P/E: 19.65
PEG ratio: 2.95
P/B: 6.74
P/S (TTM): 5.68
EV/EBITDA: 17.20

Profitability & growth

ROE (TTM): 26.4%
Operating margin: 27.4%
Revenue growth YoY: 9.9%
Dividend yield: 2.3%
Beta: 0.33

Last earnings

Apr 14, 2026 · Estimate $2.68 · Reported $2.70

Analyst estimate. Actual results often differ.

Ratios are point-in-time. Historical metrics — no guarantees about what comes next.

News & Sentiment

50 articles · sorted by date

Page 1 of 3 · 50 total

Via 3rd party. Not a recommendation or advice by The Balanced Investor Club. See disclaimer.

About Johnson & Johnson

Company profile

Johnson & Johnson (J&J) is an American multinational corporation founded in 1886 that develops medical devices, pharmaceuticals, and consumer packaged goods. Its common stock is a component of the Dow Jones Industrial Average and the company is ranked No. 36 on the 2021 Fortune 500 list of the largest United States corporations by total revenue. Johnson & Johnson is one of the world's most valuable companies, and is one of only two U.S.-based companies that has a prime credit rating of AAA, higher than that of the United States government.

Classification

Sector: Healthcare
Industry: Drug Manufacturers - General
Exchange: NYSE
Country: USA
Currency: USD

Company profile

HQ: ONE JOHNSON & JOHNSON PLAZA, NEW BRUNSWICK, NJ
Fiscal year end: December
Latest quarter: Mar 31, 2026

Market cap$546.90B

Shares outstanding$2.41B

52W high$251.71

52W low$142.16

Educational content · Not investment advice or recommendations

We're educators, not advisors. Your decisions are your own. Disclaimer

Overview

JNJ

Market Comparison

Fundamentals

Wall Street coverage

Valuation

Profitability & growth

News & Sentiment

Johnson & Johnson study backs Abiomed Impella 5.5 in non-shock, high-risk patients

Nanobiotix announces FDA acceptance of NANORAY-312 study protocol amendment

Head and neck cancer trial skips interim check, moves readout up

Aptar Injectable Sales Soar Amid Pharmaceutical Production Boom

ABBV Stock Up 5% on Robust Q1 Performance: Time to Buy, Sell or Hold?

Sanofi SA Stock (SNY) Moved Down by 5.57% on May 4: What Investors Need To Know

Johnson & Johnson’s (JNJ) Accelerating Growth Justifies the Higher Multiple

CAPLYTA® (lumateperone) showed greatest improvement across key efficacy outcomes among adjunctive MDD treatments in new network meta-analysis

3 Year Results in Patients With GA Presented at Foundation Fighting Blindness Retinal Innovation Summit 2026

Legend Biotech Expands Scientific Advisory Expertise to Inform Future Growth

Cullinan Associates Inc. Purchases 7,051 Shares of Johnson & Johnson $JNJ

Fifth Third Bancorp Acquires 28,353 Shares of Johnson & Johnson $JNJ

Jim Cramer Believes Competitors Might Hurt Intuitive Surgical

Johnson & Johnson becomes the latest pharmaceutical company to sign on to TrumpRx

Johnson & Johnson $JNJ Shares Bought by W.G. Shaheen & Associates DBA Whitney & Co

Johnson & Johnson Sells 341,693 Shares of Adicet Bio, Inc. $ACET

5,538 Shares in AbbVie Inc. $ABBV Acquired by Legacy Edge Advisors LLC

Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) Given Consensus Recommendation of "Moderate Buy" by Analysts

331,164 Shares in Protagonist Therapeutics, Inc. $PTGX Bought by Jennison Associates LLC

Protagonist Therapeutics Inc. (PTGX): Billionaire Tom Steyer Likes Upside Potential of This Stock

About Johnson & Johnson

Classification

Company profile

JNJ

Market Comparison

JNJ Market Analysis

Overview

JNJ

Market Comparison

Fundamentals

Wall Street coverage

Valuation

Profitability & growth

News & Sentiment

Johnson & Johnson study backs Abiomed Impella 5.5 in non-shock, high-risk patients

Nanobiotix announces FDA acceptance of NANORAY-312 study protocol amendment

Head and neck cancer trial skips interim check, moves readout up

Aptar Injectable Sales Soar Amid Pharmaceutical Production Boom

ABBV Stock Up 5% on Robust Q1 Performance: Time to Buy, Sell or Hold?

Sanofi SA Stock (SNY) Moved Down by 5.57% on May 4: What Investors Need To Know

Johnson & Johnson’s (JNJ) Accelerating Growth Justifies the Higher Multiple

CAPLYTA® (lumateperone) showed greatest improvement across key efficacy outcomes among adjunctive MDD treatments in new network meta-analysis

3 Year Results in Patients With GA Presented at Foundation Fighting Blindness Retinal Innovation Summit 2026

Legend Biotech Expands Scientific Advisory Expertise to Inform Future Growth

Cullinan Associates Inc. Purchases 7,051 Shares of Johnson & Johnson $JNJ

Fifth Third Bancorp Acquires 28,353 Shares of Johnson & Johnson $JNJ

Jim Cramer Believes Competitors Might Hurt Intuitive Surgical

Johnson & Johnson becomes the latest pharmaceutical company to sign on to TrumpRx

Johnson & Johnson $JNJ Shares Bought by W.G. Shaheen & Associates DBA Whitney & Co

Johnson & Johnson Sells 341,693 Shares of Adicet Bio, Inc. $ACET

5,538 Shares in AbbVie Inc. $ABBV Acquired by Legacy Edge Advisors LLC

Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) Given Consensus Recommendation of "Moderate Buy" by Analysts

331,164 Shares in Protagonist Therapeutics, Inc. $PTGX Bought by Jennison Associates LLC

Protagonist Therapeutics Inc. (PTGX): Billionaire Tom Steyer Likes Upside Potential of This Stock

About Johnson & Johnson

Classification

Company profile

JNJ

Market Comparison